Alexion Uses Excess Cash To Buy Strikingly Similar Synageva
This article was originally published in The Pink Sheet Daily
Executive Summary
At a hefty $8.4 billion price tag for a clinical-stage company, Alexion is betting heavily that Synageva’s Kanuma, filed for approval at FDA and EMA, will become an ultra-orphan blockbuster like Soliris.
You may also be interested in...
Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
Two Companies, One Owner; US FDA Sends Warning Letters To Same Address For Similar Issues
Two Massachusetts-based infusion pump manufacturers with the same founder and CEO received warning letters from the US FDA for similar violations.
Swiss Finally Beat EMA On New Drug Approval Times
More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.